Interaction Between Sibutramine and Cyclosporine

  title={Interaction Between Sibutramine and Cyclosporine},
  author={Ga{\"e}tan Clerbaux and Eric Goffin and Yves Pirson},
  journal={American Journal of Transplantation},
Obesity is common after renal transplantation and is associated with significant decreased patient and graft survival rates (1). A safe and effective pharmacological approach to induce and maintain significant weight loss would therefore be welcomed in affected patients. Sibutramine is a recently released tertiary amine that causes inhibition of neuronal re-uptake of both epinephrine and serotonine at central nervous system sites affecting satiety. Its efficacy to induce and maintain weight… Expand

Topics from this paper

Obesity in kidney transplant recipients and candidates.
  • K. Potluri, S. Hou
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2010
In the authors' opinion, patient death and transplant failure rates in patients with BMI of 30-35 kg/m(2) are low enough that these individuals should not be excluded from transplant. Expand
Post Kidney Transplant: Obesity
This chapter will delve into the epidemiology, and risk factors for post-transplant obesity, as well as discuss strategies for prevention and management. Expand
The Safety Profiles of Orlistat and Sibutramine: Results of Prescription‐Event Monitoring Studies in England
Introduction: Observational cohort studies were conducted using prescription‐event monitoring (PEM) to examine the safety profiles of the anti‐obesity agents orlistat and sibutramine. Adverse eventsExpand
Interactions with Drugs and Dietary Supplements Used For Weight Loss
Although multiple anti-obesity agents have progressed through the development process, few drug products have made it through the approval process due to safety or lack of efficacy concerns, and overweight or obese patients may turn to less regulated dietary supplements as a means to assist in weight loss. Expand
La identificacion, correccion and eventual prevencion of las complicaciones secundarias al trasplante renal obliga a la actuacion multi- e inter-disciplinaria en todos los dominios del estado of salud del paciente trasplantado. Expand
First Reports of Adverse Drug Reactions (ADRs) in Recent Weeks
  • International Journal of Pharmaceutical Medicine
  • 2012


Effect of sibutramine on weight maintenance after weight loss: a randomised trial
Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease. Expand
Sibutramine: A Serotonin–Norepinephrine Reuptake-Inhibitor for the Treatment of Obesity
Based on anorectic efficacy data, sibutramine, a serotonin–norepinephrine reuptake-inhibitor, is a viable therapeutic option for the treatment of obesity. Expand
The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death.
BMI has a very strong association with outcomes after renal transplantation independent of most of the known risk factors for patient and graft survival and is important to note that elevated BMI was significantly associated with worse graft survival independent of patient survival. Expand